Vancouver-based Forbes Medi-Tech has signed an international supply agreement with Australian firm Pan Pharmaceuticals for Reducol, a cholesterol-lowering phytosterol-based ingredient.
The initial supply agreement is for a minimum of three-years, and secures Sydney-based Pan Pharmaceuticals’ exclusive rights to supply Reducol in the form of a dietary supplement to the Australian market, and selected countries in Asia, the Middle East, Africa, as well as three countries in Europe.
“This agreement will give Forbes tremendous exposure in several key
international markets,” said Charles Butt, president and CEO of Forbes Medi-Tech: “Pan Pharmaceuticals has an intimate working knowledge of the cultures, regulatory systems and product preferences in these markets, which makes it an ideal partner for Forbes.”
Reducol is used in dietary supplements in the form of tablets capsules and soft-gel capsules.

US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData